How would you treat a patient with symptomatic and rapidly progressing metastatic HR+, HER2 low breast cancer with PIK3CA WT, ESR1 mutated, TMB high after progression on CDK 4/6 inhibitor, a taxane, and T-DXd?  

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at NYU Winthrop Hospital
Can use capivasertib with fulvestrant - CAPItello-...
Medical Oncologist at Loyola University Chicago Stritch School of Medicine
@Mohammed F. Ali and @Robert Wesolowski have you m...
Medical Oncologist at University of Wisconsin Hospital & Clinics
@Elizabeth Henry, I haven't but, capivasertib is ...
Sign in or Register to read more